Small-Molecule Inhibition of MuRF1 Prevents Early Disuse-Induced Diaphragmatic Dysfunction and Atrophy
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24043637 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Fernando Ribeiro und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomy, Institute of Biomedical Sciences, University of São Paulo, São Paulo 05508-000, Brazil. Hauptthemen laut MEDLINE: Diaphragm, Muscular Atrophy, Ubiquitin-Protein Ligases, Tripartite Motif Proteins. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: São Paulo Research Foundation, German Centre for Cardiovascular Research, National Council for Scientific and Technological Development (CNPq).
Abstract (Originalsprache)
In clinical conditions such as diaphragm paralysis or mechanical ventilation, disuse-induced diaphragmatic dysfunction (DIDD) is a condition that poses a threat to life. MuRF1 is a key E3-ligase involved in regulating skeletal muscle mass, function, and metabolism, which contributes to the onset of DIDD. We investigated if the small-molecule mediated inhibition of MuRF1 activity (MyoMed-205) protects against early DIDD after 12 h of unilateral diaphragm denervation. Wistar rats were used in this study to determine the compound’s acute toxicity and optimal dosage. For potential DIDD treatment efficacy, diaphragm contractile function and fiber cross-sectional area (CSA) were evaluated. Western blotting investigated potential mechanisms underlying MyoMed-205’s effects in early DIDD. Our results indicate 50 mg/kg bw MyoMed-205 as a suitable dosage to prevent early diaphragmatic contractile dysfunction and atrophy following 12 h of denervation without detectable signs of acute toxicity. Mechanistically, treatment did not affect disuse-induced oxidative stress (4-HNE) increase, whereas phosphorylation of (ser632) HDAC4 was normalized. MyoMed-205 also mitigated FoxO1 activation, inhibited MuRF2, and increased phospho (ser473) Akt protein levels. These findings may suggest that MuRF1 activity significantly contributes to early DIDD pathophysiology. Novel strategies targeting MuRF1 (e.g., MyoMed-205) have potential therapeutic applications for treating early DIDD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anatomy, Institute of Biomedical Sciences, University of São Paulo, São Paulo 05508-000, Brazil.
- DZHK Partner Site Mannheim-Heidelberg, Medical Faculty Mannheim, University of Heidelberg, 68169 Mannheim, Germany.
- Myomedix GmbH, 69151 Neckargemünd, Germany.
ORCID-Profile: Fernando Ribeiro, Paula K N Alves, Julio C B Ferreira, Siegfried Labeit, Anselmo S Moriscot
Förderung
- São Paulo Research Foundation
- German Centre for Cardiovascular Research
- National Council for Scientific and Technological Development (CNPq)
- DZHK
Zitieren
APA
Ribeiro, F., Alves, P. K. N., Bechara, L. R. G., Ferreira, J. C. B., Labeit, S., & Moriscot, A. S. (2023). Small-Molecule Inhibition of MuRF1 Prevents Early Disuse-Induced Diaphragmatic Dysfunction and Atrophy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24043637
Vancouver
Ribeiro F, Alves PKN, Bechara LRG, Ferreira JCB, Labeit S, Moriscot AS. Small-Molecule Inhibition of MuRF1 Prevents Early Disuse-Induced Diaphragmatic Dysfunction and Atrophy. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24043637
BibTeX
@article{Ribeiro2023,
author = {Ribeiro, Fernando and Alves, Paula K N and Bechara, Luiz R G and Ferreira, Julio C B and Labeit, Siegfried and Moriscot, Anselmo S},
title = {Small-Molecule Inhibition of MuRF1 Prevents Early Disuse-Induced Diaphragmatic Dysfunction and Atrophy},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24043637}
}
EUVIMED